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The implantable cardioverter-defibrillator (ICD) is an example of an effective intervention
with high up-front costs and delayed benefits. It has become a proven and well-accepted
therapy not only for secondary but also for primary prevention of sudden cardiac death
in patients with ischemic and non-ischemic heart disease. In recent years, the interna-
tional guidelines have extended the indications to the prophylactic ICD, increasing the
number of eligible patients and, together, the financial challenges of a widespread
implementation. In this article, we review the available economic tools that can help
address the ICD cost issue. We think that the awareness of such knowledge may facilitate
dialogues between physicians, administrators and policy-makers, and help foster rational
decision making.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
New opportunities in the field of preventive and curative med-
icine are now available thanks to rapid technological advances.
However, since many effective new interventions entail
considerable financial cost, affordability issues are rising,
mostly because of limited financial resources. Primary preven-
tion is a particularly challenging area, since often thebenefits of
an intervention could be perceived only many years later1,2;
therefore, expensive primary prevention initiatives may cause
diffidence, or even active resistance, due to the financial bur-
dens which inevitably accompany their widespread adoption.38; fax: þ39 (0) 51344859.
t (G. Boriani).
2014, Cardiological SocietThe implantable cardioverter-defibrillator (ICD) is an
example of an effective intervention with high up-front costs
and delayed benefits.4e9 It has become a proven and well-
accepted therapy not only for secondary but also for primary
prevention of sudden cardiac death in patients with ischemic
and non-ischemic heart disease. In recent years, the inter-
national guidelines have extended the indications to the
prophylactic ICD, increasing the number of eligible patients7e9
and, together, the financial challenges of a widespread
implementation.2,3,10
In this article, we will discuss how the available economic
tools can help address the ICD cost issue, and, according to the
available estimates, how it’s desirable a cultural change in they of India. All rights reserved.
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and approach this sort of issue.2. The ICD cost issue
Despite the decline in overall mortality from cardiovascular
diseases observed over the last decade, the proportion of
deaths due to sudden cardiac death has been increasing: in
Western countries, sudden cardiac death is responsible for
more victims each year than AIDS, lung cancer, breast cancer,
or stroke.11,12 In economically developed countries, use of ICDs
for primary prevention of sudden cardiac death can be seen as
a relevant publichealth consideration: indeed, evidence froma
series of large randomized trials now provides very strong
evidence that use of ICDs improves overall survival at 2e5
years in appropriately selected patients with left ventricular
dysfunction.5,7,9 The ICD is commonly perceived as a rather
expensive therapy with high up-front costs due to the device
itself and the implant followedover timebymaintenance costs
for device replacement and possible complications.2 Despite
marked price reductions in the last decade, themain limit to a
full acceptance and adoption of ICD therapy, especially
regarding primary prevention, is still the cost issue2,13; this
matter concerns all the organizations involved in the care of
patients with heart failure, not only electrophysiologists.
The role of ICD therapy has expanded hugely since the
device was first conceived by Dr. Michel Mirowski over 25
years ago for secondary sudden cardiac death prevention in
selected patients with documented ventricular tachyar-
rhythmias.14,15 Demonstrated efficacy of ICDs in primary
prevention was initially established in patients with ischemic
heart disease (MADIT I, MUSTT, MADIT II trials),4e9 and was
then extended to patients with heart failure (NYHA class II
and III) of either ischemic or non-ischemic etiology (SCD-HeFT
trial).4e9 These findings were progressively translated into the
recommendations for ICD implantation provided by
consensus guideline: the widening of evidence-based in-
dications to implantation is expected to lead to an impressive
rise in the potential number of implants. In response to con-
cerns that increased use of ICDs may cause a dramatic
financial burden on healthcare systems, a debate is emerging
on how to find a balance between the weight of evidence and
spending on ICD therapy.2
Whereas there is broad scientific consensus regarding the
efficacy of using ICDs in appropriately selected patients, a
search to reach a similar consensus on the cost issue appears
more problematic: the affordability of relatively expensive
treatments of clearly proven efficacy is a delicate issue, that
should be kept separate from clinical guidelines based on
scientific evidence of efficacy.16,17
Despite the mounting costs that healthcare systems have
had to face in recent years, inmanyhigh-income countries the
balancing of benefits against costs has yet to becomeaprimary
criterion for deciding whether a medical treatment should be
covered by public services (the U.K. National Institute of
Clinical Excellence is a prominent exception in this respect).
Inmany European countries, consideration of the effects of
adopting a new treatment has mainly been based on strictly
financial concerns rather than on in-depth economic analysis,with a consequent tendency to limit or even reject costly new
treatments, despite proven clinical efficacy.18
Affordability considerations will inevitably vary between
countries with very different healthcare systems and econo-
mies: nevertheless, analytical tools do exist to help address
specific questions of affordability within national, regional or
even local contexts.3. Available tools for economic analysis
A range of economic tools allows us to weigh up the benefits
and the costs of given medical treatments, providing a formal
economic basis for implementation decisions. In order to go
beyond the assessment of financial burden of competing
candidate treatments, a genuine economic approach should
include cost-effectiveness and cost-utility estimates,
expressed in terms of ‘years of life saved’ (YLS) and ‘quality-
adjusted life years’ (QALY) gained, respectively, and cost-
benefit analysis, which assigns a monetary value to thera-
peutic benefits.18 These tools address questions such as “which
treatment is most likely to provide maximum health benefits
for a given level of financial resources?” or “which treatment
provides a given level of health benefits at the lowest cost?”;
the different approaches generate different measures.18
Cost-effectiveness analysis aims to assess the cost of any
therapeutic intervention with respect to its predictable
outcome benefits.18 “Incremental cost-effectiveness” analysis
compares alternative therapeutic strategies and generate a
cost-effectiveness ratio, often expressed in dollars per year of
life saved ($/YLS). In the literature,13,18,19 treatments are
sometimes referred to vary from “very attractive” to “abso-
lutely unfavorable” depending on the cost-effectiveness ratio.
As shown in Table 1, cost-effectiveness ratios can vary
considerably depending on the subset of treated population:
identification of high-risk patients13 seems to be the single
most important factor in order to reach a favorable figure.13
Notably, long-term use of relatively “cheap” medications
which do not exert major long-term survival benefits can
generate unfavorable cost-effectiveness ratios (examples
include lipid lowering treatments or antiplatelet drugs in pa-
tients at relatively low risk); conversely, when high initial
treatment costs are offset by long-term survival benefits (as
can be the case with ICDs) the cost-effectiveness ratio may
turn out to be surprisingly favorable. Improved risk stratifi-
cation may allow identification of patients for whom the op-
tion of ICD implantation appears more favorable or attractive,
and thus, it might help optimize health outcomes within the
context of financial restrictions.20,214. Available economic estimates for use of
ICDs
Various economic models generated a broad range of cost-
effectiveness estimates for ICDs, ranging from unfavorable
to economically attractive values.
The most authoritative cost-effectiveness analysis of ICD
therapy in the primary prevention of SCD was provided by
Sanders et al. Eight landmark ICD trials were considered, and
Table 1 e League table on the cost-effectiveness profile of
various medical interventions according to V/QALY ratio
(modified from Leyva et al and Thjissen et al).22,23
Estimates are reported in V per quality-adjusted life year
saved, or in some cases, as reported, in V per life year
saved.
Treatment V/QALY
Enalapril for heart failure 83
Intensive insulin therapy for a 25-years-old 6907
Liver transplantation 18,678*
Heart transplantation 20,115*
Primary prevention ICD in MUSTT 28,500
Primary prevention ICD in MADIT I 29,254
Primary prevention ICD in COMPANION 42,163
Primary prevention ICD in DEFINITE 43,001
Primary prevention ICD in MADIT II 45,348
Lung transplantation 55,317*
Primary prevention ICD in SCD-HeFT 58,842
ACEI for hypertension in echo-LVH 143,680
Screening at 50 years for proteinuria, then ACEI 203,177
ACEI for hypertension in unselected patients 502,880
Statin for primary prevention 38,793e1,005,760
Intensive insulin therapy for an 85-years-old 1,508,640
Legend: * ¼ V per life year saved; QALY, quality-adjusted life year
saved; ACEI, angiotensin-converting enzyme inhibitors; echo-LVH,
left ventricular hypertrophy according to echocardiography.
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mental cost-effectivenesswas used to compare ICD therapy to
control therapy over a lifetime horizon. Whilst in two of those
trials the lack of clinical efficacy of ICD therapy led to a lack of
cost-effectiveness over control therapy, in the six other trial
populations, primary prevention single-chamber ICD im-
plantation was projected to add between 1.01 and 2.99 QALYs
and the incremental cost-effectiveness (discounted at 3%)
ranged from V28.500 to V58.842 per QALY gained.22 Impor-
tantly, the cost-effectiveness ratio was below $100.000 in all
the trial populations, as long as the effectiveness of the ICD
was assumed to continue for at least 7 years.23
Concerning the European healthcare systems, a meta-
analysis by Cowie et al examined the lifetime benefits, costs
and cost-effectiveness of prophylactic implantation of an ICD
adopting the perspective of the Belgian healthcare system: in
this analysis, primary prevention single-chamber ICD implan-
tation was associated with an estimated mean LY and QALY
gain of 1.88 and 1.57, respectively, and an estimated mean life-
time cost per QALY gained of V31.717 according to the proba-
bilistic sensitivity analysis.24 These results are comparablewith
those reported by Thijssen et al based on clinical data and costs
derived from routine clinical practice.22 In the latter analysis it
was shown that single and dual-chamber ICDs are cost-
effective as primary prevention therapy also in the real world.
An important source of variability is the horizon within
which cost-effectiveness is estimated.25,26 In this respect, a
review of eight trials has shown that the benefit from ICD
therapy increases non-linearly with the square of time.27 This
implies that at 3 years the LYS per ICD implanted in MADIT
was 4.6 times that observed at 1 year. The increase in benefit
from ICD therapy with time from implantation has important
implications for its cost-effectiveness, particularly as the
therapy involves high up-front costs. For instance, in the SCD-HeFT study, the base-case lifetime ICER was V27.579 per
QALY: model projections revealed that the ICER per LYS was
reduced fromV150.526 at 5 years, and toV35.920 at 14 years.23
An extension of device longevity can be achieved in most
recent devices reducing long-term costs of ICD therapy; this
may further improve its cost-effectiveness, as well as the cost
per day of ICD therapy.28,29
The most comprehensive available analysis on cost-
effectiveness was commissioned by NICE specifically for the
UK national context.30,31 This study included a decision ana-
lytic model based on evidence critically extracted from 8
randomized controlled trials, 2 systematic reviews and a
meta-analysis. Taking into account both secondary and pri-
mary prevention, the results indicated that ICD use can lead to
variable survival improvements, with incremental cost-
effectiveness values ranging from 98,000 to over 379,000
$/QALY depending on mortality risk and the assumptions
adopted.31 This commissioned work exemplifies how cost-
effectiveness analysis can be applied to a specific national
context to guide rational health care decision making.
As regards cost-benefit analysis, to our knowledge there is
only one currently available study of ICDs in primary pre-
vention of sudden cardiac death.32 This study challenges the
widespread assumption that ICDs should be viewed as a
worrying financial burden for society. The researchers used
the results of SCD-HeFT to compare cost-benefit values esti-
mated for ICDs in comparison with amiodarone (the most
widely used prophylactic antiarrhythmic drug). The conclu-
sion was that in countries where society values a life more
than V2 million, ICDs can be considered a more worthwhile
long-term investment than amiodarone for primary preven-
tion of sudden cardiac death.32 This cost-benefit evaluation
may radically change the perspective of ICD use in high-risk
patients, supporting the view that this option can be seen as
a worthwhile investment not only for individual patients, but
also for society as a whole.335. Conclusions
Despite continuing price reductions, ICD cost will probably
remain a major issue in implementation of current guide-
lines.34e36 In the light of broadened indications to implantation
and locally available resources, physicians might face societal
limitations (limited economical funding) which compete with
individual imperatives (offering the best to each patient).
In this article, we have tried to illustrate how economic
analysis can provide a key tool to weigh ICD costs against
projected long-term outcome benefits. Considering the rela-
tively high up-front ICD costs, this approach seems appro-
priate for assessing whether implantation in specific subsets
of patients will eventually be more or less economically valid
in comparison with alternative treatments involving more
“continuous” costs. Most studies indicate that use of ICDs in
appropriately selected patients at high risk of sudden cardiac
death is cost-effective, and thus it can be considered a
worthwhile long-term investment.
Improved awareness of this concept among physicians,
administrators and policy-makers may help foster rational
decision making for the allocation of available resources.
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